INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
HOUSE PTR/PurchaseVerified data

Lisa C. McClain bought IBRX

Spouse · ImmunityBio, Inc. · ImmunityBio, Inc. - Common Stock

Side
BUY
Value range
$1,001 – $15K
Shares
Not disclosed
Price
—
Executed
Sep 28, 2026
Disclosed
Oct 12, 2026
Disclosure timeline14 days from execution to publication · legal deadline 45 days
Sep 28 executedOct 12, 2026 disclosed

IBRX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
24/ 100 · ROUTINE
Methodology →
  • Transaction type+14 / 20

    Purchase

  • Relative size+2 / 25

    Disclosed range starting at $1K

  • Filing timing0 / 15

    Disclosed 14 days after execution (STOCK Act deadline: 45)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · IBRX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    20
    Lisa C. McClainRSpouse
    IBRXImmunityBio, Inc.
    Purchase
    		BUY$1,001 – $15KSep 30, 2026Oct 12, 2026
    traded Sep 30, 2026
    		+12dHOUSE PTR

    Evidence

    8
    SJ
    Simon Barry J.Director
    IBRXImmunityBio, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$197K
    25.0K sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    5
    SC
    Selecky ChristobelDirector
    IBRXImmunityBio, Inc.
    Grant or award
    		A—
    65.6K sh
    		Jun 9, 2026Jun 10, 2026
    traded Jun 9, 2026
    		+1dSEC FORM 4

    Evidence

    9
    ML
    Maxwell LindaDirector
    IBRXImmunityBio, Inc.
    Grant or award
    		A—
    65.6K sh
    		Jun 9, 2026Jun 10, 2026
    traded Jun 9, 2026
    		+1dSEC FORM 4

    Evidence

    19
    SC
    Sachs David C.Chief Financial Officer
    IBRXImmunityBio, Inc.
    Tax withholding
    		F$296K
    42.6K sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    21
    SC
    Sachs David C.Chief Financial Officer
    IBRXImmunityBio, Inc.
    Option exercise
    		M—
    82.2K sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    17
    SC
    Sachs David C.Chief Financial Officer
    IBRXImmunityBio, Inc.
    Option exercise
    		M—
    82.2K sh
    		Feb 10, 2026Feb 12, 2026
    traded Feb 10, 2026
    		+2dSEC FORM 4

    Evidence

    29
    SC
    Selecky ChristobelDirector
    IBRXImmunityBio, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$250K
    50.0K sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    0
    SC
    Selecky ChristobelDirector
    IBRXImmunityBio, Inc.
    Option exercise · 10b5-1 plan
    		M$75K
    25.0K sh
    		Jan 20, 2026Jan 21, 2026
    traded Jan 20, 2026
    		+1dSEC FORM 4

    Evidence

    17
    SC
    Selecky ChristobelDirector
    IBRXImmunityBio, Inc.
    Option exercise · 10b5-1 plan
    		M—
    50.0K sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    16
    SC
    Selecky ChristobelDirector
    IBRXImmunityBio, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$188K
    25.0K sh
    		Jan 20, 2026Jan 21, 2026
    traded Jan 20, 2026
    		+1dSEC FORM 4

    Evidence

    3
    SC
    Selecky ChristobelDirector
    IBRXImmunityBio, Inc.
    Option exercise · 10b5-1 plan
    		M—
    25.0K sh
    		Jan 20, 2026Jan 21, 2026
    traded Jan 20, 2026
    		+1dSEC FORM 4

    Evidence

    8
    SC
    Selecky ChristobelDirector
    IBRXImmunityBio, Inc.
    Option exercise · 10b5-1 plan
    		M$149K
    50.0K sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    House Periodic Transaction Report
    Publisher
    Clerk of the U.S. House of Representatives
    Document ID
    20035585

    Timestamps

    Event (reported)
    Sep 28, 2026
    Published
    Oct 12, 2026
    Ingested by INSIDER
    Nov 4, 22:39 UTC
    Last re-read
    Nov 5, 15:29 UTC

    Extracted facts

    Filer
    Lisa C. McClain
    Role
    SpouseAs filed: “SP”
    Transaction
    PurchaseAs filed: “P”
    Asset
    ImmunityBio, Inc. - Common Stock
    Ticker
    IBRX
    Reported value
    $1,001 – $15KAs filed: “$1,001 - $15,000”
    Execution date (reported)
    Sep 28, 2026
    Notification date (reported)
    Oct 1, 2026
    Days from execution to publication
    14

    Calculation

    Midpoint = (low + high) / 2. Used only to rank and sum ranges; the true value can be anywhere in the range.

    • Low: $1,001
    • High: $15,000

    = $8,001

    What this establishes

    Lisa C. McClain reported a purchase of ImmunityBio, Inc. - Common Stock (owner: spouse). Members report a value range, not an exact amount, and do not report share counts or prices. Dates are as entered by the filer. A trade report is not evidence of wrongdoing.

    Extraction

    Method
    PDF text extraction
    Confidence
    1.00
    Spouse
    Lisa C. McClainbioguide:M001136
    Issuer
    ImmunityBio, Inc.cik:0001326110

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.